Comparing two PET imaging agents for prostate cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a new PET imaging agent, [68Ga]Ga-PSMA-D5, in diagnosing prostate cancer, detecting recurrence, and identifying metastasis. It involves a head-to-head comparison with the established agent, [68Ga]Ga-PSMA-11, focusing on biodistribution and diagnostic accuracy. Patients will undergo both imaging examinations within a two-week period, and the results will be analyzed for sensitivity, specificity, and lesion identification. The study aims to provide insights into which imaging agent offers better diagnostic capabilities for prostate cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged from 18 to 90 years old;
* Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
* Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
* simultaneous \[68Ga\]Ga-PSMA-D5 and \[68Ga\]Ga-PSMA-11 examinations within two weeks;
* Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
* Sign informed consent.

Exclusion Criteria:

* Patients who cannot cooperate with the examination;
* Concurrent malignant tumors;
* Previous alcohol allergy;
* Patients with liver and kidney dysfunction;
* Other circumstances deemed by the investigator to be inappropriate for trial participation.

Where it's running

• The First Affiliated Hospital of China University of Science and Technology（Anhui Provincial Hospital）
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Qiang Xie, MD
• Email: xieqiang1980@ustc.edu.cn
• Phone: +8613721108043

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XACP3 PET/CT for detecting prostate cancer lesions

  This study will test whether 68Ga-XACP3 PET/CT can find tumor lesions in adults with prostate cancer or suspected recurrence compared with the standard 68Ga-PSMA PET/CT.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07242014

• Comparing two PET imaging agents for prostate cancer diagnosis

  This study is testing a new PET imaging agent for prostate cancer to see if it works better than an existing one in diagnosing the disease and spotting any spread or recurrence.

  Recruiting Early Phase 1 Anhui Provincial Hospital · Hefei, Anhui · NCT06756334

• Registry assessing PSMA PET outcomes in prostate cancer

  This study is testing if PSMA PET imaging can help doctors better understand the outcomes for men with prostate cancer compared to traditional methods.

  Recruiting University Hospital, Essen · Essen · NCT06320223

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.